Freemelt’s three largest shareholders, Industrifonden, Bengt Julander and Coeli, together with the Board and management, have expressed their intention to exercise their series TO1 warrants during the upcoming exercise period in June 2026. These statements of intent correspond to around 44 per cent of the approximately 40 million outstanding warrants.
The warrants were issued in connection with Freemelt’s rights issue in February 2025 and formed part of the issued units. They provided investors with attractive terms while also potentially supplying the Company with additional growth capital. Each warrant entitles the holder to subscribe for one new share during the period from 2 June up to and including 16 June 2026. The subscription price will be set at 70 per cent of the volume-weighted average price (VWAP) during the period from 18 May up to and including 29 May 2026, but not lower than the share’s quota value and not higher than SEK 1.33 per share.
The warrants form part of the Company’s financing strategy and strengthen its ability to further develop its broader offering, which includes production services for qualified parts and assemblies for applications primarily in defence and energy. Within medtech, where the transition to additive manufacturing is more advanced, the focus remains on machine sales to leading OEMs. The capital contribution from the warrants will be used for industrialisation and operational optimisation, while also strengthening the Company’s working capital during the commercialisation phase. In addition, it will enable continued R&D work, further reinforcing Freemelt’s position within the Company’s prioritised focus areas.
“The support from our largest shareholders is clear evidence of confidence in our technology, our strategy and our ability to continue driving the industrialisation of additive manufacturing. The capital injection from the warrants strengthens our ability to accelerate commercialisation and deliver on our growth targets,” says Daniel Gidlund, CEO of Freemelt.